首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Identification of class Ⅰ MHC-associated phosphopeptides as targets for cancer immunotherapy
【24h】

Identification of class Ⅰ MHC-associated phosphopeptides as targets for cancer immunotherapy

机译:鉴定Ⅰ类MHC相关磷酸肽作为癌症免疫治疗的靶标

获取原文
获取原文并翻译 | 示例
       

摘要

Alterations in phosphorylation of cellular proteins are a hallmark of malignant transformation. Degradation of these phosphopro-teins could generate cancer-specific class Ⅰ MHC-associated phosphopeptides recognizable by CD8~+ T lymphocytes. In a comparative analysis of phosphopeptides presented on the surface of melanoma, ovarian carcinoma, and B lymphoblastoid cells, we find 5 of 36 that are restricted to the solid tumors and common to both cancers. Differential presentation of these peptides can result from differential phosphorylation of the source proteins. Recognition of the peptides on cancer cells by phosphopeptide-specific CD8~+ T lymphocytes validates the potential of these phosphopeptides as immunotherapeutic targets.
机译:细胞蛋白磷酸化的改变是恶性转化的标志。这些磷酸化蛋白的降解可产生CD8〜+ T淋巴细胞可识别的癌症特异性的Ⅰ类MHC相关的磷酸肽。在对黑色素瘤,卵巢癌和B淋巴母细胞表面上存在的磷酸肽的比较分析中,我们发现了36​​种中的5种局限于实体瘤,并且在两种癌症中都是常见的。这些肽的差异表达可能是源蛋白的差异磷酸化导致的。磷酸肽特异性CD8〜+ T淋巴细胞对癌细胞上的肽的识别证实了这些磷酸肽作为免疫治疗靶标的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号